Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori S.r.l.

Running trials

• Recruiting

  An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

  NCT05907057· Phase 3· Source

• Recruiting

  Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and resectable primary colorectal cancer: the UNICORN study.

  2022-501308-90-00· Phase 2· Source

• Active, not recruiting

  Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2

  2022-500861-29-00· Phase 3· Source

• Active, not recruiting

  A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

  NCT04025879· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Source

• Completed

  Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy

  2022-500652-37-00· Phase 2· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

  NCT03142334· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Source